Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

National and regional modeling of distinct RSV seasonality thresholds for antigen and PCR testing in the United States.

Ambrose CS, Steed LL, Brandon M, Frye K, Olajide IR, Thomson G.

J Clin Virol. 2019 Nov;120:68-77. doi: 10.1016/j.jcv.2019.09.010. Epub 2019 Sep 20.

PMID:
31590113
2.

Patient and physician preferences for attributes of biologic medications for severe asthma.

Gelhorn HL, Balantac Z, Ambrose CS, Chung YN, Stone B.

Patient Prefer Adherence. 2019 Jul 25;13:1253-1268. doi: 10.2147/PPA.S198953. eCollection 2019.

3.

SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.

Anderson EJ, DeVincenzo JP, Simões EAF, Krilov LR, Forbes ML, Pannaraj PS, Espinosa CM, Welliver RC, Wolkoff LI, Yogev R, Checchia PA, Domachowske JB, Halasa N, McBride SJ, Kumar VR, McLaurin KK, Rizzo CP, Ambrose CS.

Am J Perinatol. 2019 Apr 16. doi: 10.1055/s-0039-1681014. [Epub ahead of print]

4.

Association of Prior Vaccination With Influenza Vaccine Effectiveness in Children Receiving Live Attenuated or Inactivated Vaccine.

McLean HQ, Caspard H, Griffin MR, Gaglani M, Peters TR, Poehling KA, Ambrose CS, Belongia EA.

JAMA Netw Open. 2018 Oct 5;1(6):e183742. doi: 10.1001/jamanetworkopen.2018.3742.

5.

Is it RSV?

Ambrose CS.

Health Sci Rep. 2018 Oct 12;1(12):e97. doi: 10.1002/hsr2.97. eCollection 2018 Dec.

6.

Live Attenuated and Inactivated Influenza Vaccine Effectiveness.

Chung JR, Flannery B, Ambrose CS, Bégué RE, Caspard H, DeMarcus L, Fowlkes AL, Kersellius G, Steffens A, Fry AM; Influenza Clinical Investigation for Children Study Team; Influenza Incidence Surveillance Project; US Influenza Vaccine Effectiveness Network.

Pediatrics. 2019 Feb;143(2). pii: e20182094. doi: 10.1542/peds.2018-2094. Epub 2019 Jan 7.

PMID:
30617239
8.

Response to Morimoto and Takeishi 2018.

Mallory RM, Ambrose CS.

Vaccine. 2019 Aug 14;37(35):4852. doi: 10.1016/j.vaccine.2018.09.066. Epub 2018 Oct 3. No abstract available.

PMID:
30292457
9.

2015-2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States.

Poehling KA, Caspard H, Peters TR, Belongia EA, Congeni B, Gaglani M, Griffin MR, Irving SA, Kavathekar PK, McLean HQ, Naleway AL, Ryan K, Talbot HK, Ambrose CS.

Clin Infect Dis. 2018 Feb 10;66(5):665-672. doi: 10.1093/cid/cix869.

10.

Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States.

Parikh RC, McLaurin KK, Margulis AV, Mauskopf J, Ambrose CS, Pavilack M, Candrilli SD.

Infect Dis Ther. 2017 Dec;6(4):477-486. doi: 10.1007/s40121-017-0167-9. Epub 2017 Sep 2.

11.

Live-Attenuated Influenza Vaccine Effectiveness in Children From 2009 to 2015-2016: A Systematic Review and Meta-Analysis.

Caspard H, Mallory RM, Yu J, Ambrose CS.

Open Forum Infect Dis. 2017 Jul 24;4(3):ofx111. doi: 10.1093/ofid/ofx111. eCollection 2017 Summer.

12.

Corrigendum to "Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2-49years" [Vaccine 35 (2017) 1254-1258].

Baxter R, Eaton A, Hansen J, Aukes L, Caspard H, Ambrose CS.

Vaccine. 2017 May 25;35(23):3152. doi: 10.1016/j.vaccine.2017.04.061. Epub 2017 Apr 27. No abstract available.

13.

Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014-2015 season.

McLean HQ, Caspard H, Griffin MR, Poehling KA, Gaglani M, Belongia EA, Talbot HK, Peters TR, Murthy K, Ambrose CS.

Vaccine. 2017 May 9;35(20):2685-2693. doi: 10.1016/j.vaccine.2017.03.085. Epub 2017 Apr 10.

14.

Respiratory syncytial virus hospitalization risk in the second year of life by specific congenital heart disease diagnoses.

Friedman D, Fryzek J, Jiang X, Bloomfield A, Ambrose CS, Wong PC.

PLoS One. 2017 Mar 2;12(3):e0172512. doi: 10.1371/journal.pone.0172512. eCollection 2017.

15.

Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections.

Ambrose CS.

Pediatr Infect Dis J. 2017 Mar;36(3):348. doi: 10.1097/INF.0000000000001432. No abstract available.

16.

Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2-49years.

Baxter R, Eaton A, Hansen J, Aukes L, Caspard H, Ambrose CS.

Vaccine. 2017 Mar 1;35(9):1254-1258. doi: 10.1016/j.vaccine.2017.01.062. Epub 2017 Feb 2. Erratum in: Vaccine. 2017 May 25;35(23 ):3152.

17.

Correction: Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation.

Simões EA, Anderson EJ, Wu X, Ambrose CS.

PLoS One. 2016 Dec 13;11(12):e0168882. doi: 10.1371/journal.pone.0168882. eCollection 2016.

18.

Letter to the editor: Potential causes of the decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines.

Ambrose CS, Bright H, Mallory R.

Euro Surveill. 2016 Nov 10;21(45). pii: 30394. doi: 10.2807/1560-7917.ES.2016.21.45.30394. No abstract available.

19.

Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation.

Simões EA, Anderson EJ, Wu X, Ambrose CS.

PLoS One. 2016 Nov 29;11(11):e0166226. doi: 10.1371/journal.pone.0166226. eCollection 2016. Erratum in: PLoS One. 2016 Dec 13;11(12 ):e0168882.

20.

Insurance Status and the Risk of Severe Respiratory Syncytial Virus Disease in United States Preterm Infants Born at 32-35 Weeks Gestational Age.

Franklin JA, Anderson EJ, Wu X, Ambrose CS, Simões EA.

Open Forum Infect Dis. 2016 Jul 29;3(3):ofw163. eCollection 2016 Sep.

21.

Association of vaccine handling conditions with effectiveness of live attenuated influenza vaccine against H1N1pdm09 viruses in the United States.

Caspard H, Coelingh KL, Mallory RM, Ambrose CS.

Vaccine. 2016 Sep 30;34(42):5066-5072. doi: 10.1016/j.vaccine.2016.08.079. Epub 2016 Sep 6.

22.

SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.

Anderson EJ, Krilov LR, DeVincenzo JP, Checchia PA, Halasa N, Simões EA, Domachowske JB, Forbes ML, Pannaraj PS, McBride SJ, McLaurin KK, Kumar VR, Ambrose CS.

Am J Perinatol. 2017 Jan;34(1):51-61. doi: 10.1055/s-0036-1584147. Epub 2016 May 27.

23.

Trends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997-2012.

Doucette A, Jiang X, Fryzek J, Coalson J, McLaurin K, Ambrose CS.

PLoS One. 2016 Apr 6;11(4):e0152208. doi: 10.1371/journal.pone.0152208. eCollection 2016.

24.

Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants.

DeVincenzo JP, Ambrose CS, Makari D, Weiner LB.

Hum Vaccin Immunother. 2016 Apr 2;12(4):971-5. doi: 10.1080/21645515.2015.1115936. Epub 2016 Feb 18.

25.

A systematic review of the efficacy of live attenuated influenza vaccine upon revaccination of children.

Caspard H, Heikkinen T, Belshe RB, Ambrose CS.

Hum Vaccin Immunother. 2016 Jul 2;12(7):1721-7. doi: 10.1080/21645515.2015.1115164. Review.

26.

Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States.

Caspard H, Gaglani M, Clipper L, Belongia EA, McLean HQ, Griffin MR, Talbot HK, Poehling KA, Peters TR, Veney N, Ambrose CS.

Vaccine. 2016 Jan 2;34(1):77-82. doi: 10.1016/j.vaccine.2015.11.010. Epub 2015 Nov 14.

PMID:
26589519
27.

Receipt of palivizumab before birth hospitalization discharge among preterm infants in the United States.

La Gamma EF, Kumar VR, Wadhawan R, Ye S, Sifakis F, Ycas J, Ambrose CS.

Am J Perinatol. 2015 Sep;32(11):1017-23. doi: 10.1055/s-0034-1543951. Epub 2015 Apr 15.

PMID:
25877742
28.

The Medicaid Cost of Palivizumab.

Ambrose CS, McLaurin KK.

J Pediatric Infect Dis Soc. 2015 Mar;4(1):83-4. doi: 10.1093/jpids/piu025. Epub 2014 Apr 2. No abstract available.

29.

Standard methods based on last menstrual period dates misclassify and overestimate US preterm births.

Ambrose CS, Caspard H, Rizzo C, Stepka EC, Keenan G.

J Perinatol. 2015 Jun;35(6):411-4. doi: 10.1038/jp.2015.25. Epub 2015 Apr 2.

PMID:
25836319
30.

Intensive care unit admission rates for respiratory syncytial virus infection as a function of age in preterm infants born at 32-35-week gestation and not receiving immunoprophylaxis.

Simões EA, Ambrose CS, Wu X, Anderson EJ.

Pediatr Infect Dis J. 2015 Mar;34(3):331. doi: 10.1097/INF.0000000000000566. No abstract available.

PMID:
25742086
31.

Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.

Forbes ML, Kumar VR, Yogev R, Wu X, Robbie GJ, Ambrose CS.

Hum Vaccin Immunother. 2014;10(10):2789-94. doi: 10.4161/hv.29635.

32.

A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.

Ambrose CS, Chen X, Kumar VR.

Hum Vaccin Immunother. 2014;10(10):2785-8. doi: 10.4161/hv.32082. Epub 2014 Nov 21.

33.

Severe RSV disease in preterm infants born at 29 to 35 weeks' gestation in the United States.

Ambrose CS.

Pediatrics. 2014 Dec;134(6):e1781. doi: 10.1542/peds.2014-2901A. No abstract available.

34.

Efficacy of live attenuated influenza vaccine against influenza illness in children as a function of illness severity.

Ambrose CS, Wu X, Caspard H, Belshe RB.

Vaccine. 2014 Sep 29;32(43):5546-8. doi: 10.1016/j.vaccine.2014.07.097. Epub 2014 Aug 12.

35.

The Underrecognized Burden of Respiratory Syncytial Virus Among Infants Presenting to US Emergency Departments.

Makari D, Staat MA, Henrickson KJ, Wu X, Ambrose CS.

Clin Pediatr (Phila). 2015 Jun;54(6):594-7. doi: 10.1177/0009922814546040. Epub 2014 Aug 6. No abstract available.

36.

Seasonal influenza vaccination trends from 2007-2011 in privately insured children and adults in the United States.

Antonova E, Ambrose CS, Kern D, Block SL, Caspard H, Tunceli O.

Vaccine. 2014 Nov 12;32(48):6563-8. doi: 10.1016/j.vaccine.2014.07.009. Epub 2014 Jul 18.

37.

Editorial.

Ambrose CS, Bhattacharya J, Fox CB, McIntosh ED, Stern PL.

Ther Adv Vaccines. 2013 May;1(1):3-5. doi: 10.1177/2051013613486264. No abstract available.

38.

Methods to estimate gestational age can significantly affect study results.

Ambrose CS, Rizzo C, Caspard H.

JAMA Pediatr. 2014 Apr;168(4):388. doi: 10.1001/jamapediatrics.2013.5175. No abstract available.

PMID:
24710585
39.

Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis.

McLaurin K, Ambrose CS.

Pediatrics. 2014 Apr;133(4):e1101. doi: 10.1542/peds.2014-0077A. No abstract available.

PMID:
24692037
40.

Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.

Ambrose CS, Anderson EJ, Simões EA, Wu X, Elhefni H, Park CL, Sifakis F, Groothuis JR.

Pediatr Infect Dis J. 2014 Jun;33(6):576-82. doi: 10.1097/INF.0000000000000219.

41.

Factors associated with in-office influenza vaccination by U.S. pediatric providers.

Lin CJ, Nowalk MP, Toback SL, Ambrose CS.

BMC Pediatr. 2013 Nov 6;13:180. doi: 10.1186/1471-2431-13-180.

42.

The healthcare and societal burden associated with influenza in vaccinated and unvaccinated European and Israeli children.

Ambrose CS, Antonova EN.

Eur J Clin Microbiol Infect Dis. 2014 Apr;33(4):569-75. doi: 10.1007/s10096-013-1986-6. Epub 2013 Oct 4.

43.
44.

A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24-59 months of age.

Toback SL, Ambrose CS, Eaton A, Hansen J, Aukes L, Lewis N, Wu X, Baxter R.

Vaccine. 2013 Apr 3;31(14):1812-8. doi: 10.1016/j.vaccine.2013.01.055. Epub 2013 Feb 6.

45.

Improved timing of availability and administration of influenza vaccine through the US Vaccines for Children Program from 2007 to 2011.

Ambrose CS, Toback SL.

Clin Pediatr (Phila). 2013 Mar;52(3):224-30. doi: 10.1177/0009922812470868. Epub 2013 Jan 8.

PMID:
23299840
46.

Effectiveness of intranasal live attenuated influenza vaccine against all-cause acute otitis media in children.

Heikkinen T, Block SL, Toback SL, Wu X, Ambrose CS.

Pediatr Infect Dis J. 2013 Jun;32(6):669-74. doi: 10.1097/INF.0b013e3182840fe7.

PMID:
23271441
47.

The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adults.

Ambrose CS, Wu X.

Vaccine. 2013 Jan 30;31(6):857-60. doi: 10.1016/j.vaccine.2012.12.028. Epub 2012 Dec 20.

48.

Quadrivalent Ann Arbor strain live-attenuated influenza vaccine.

Toback SL, Levin MJ, Block SL, Belshe RB, Ambrose CS, Falloon J.

Expert Rev Vaccines. 2012 Nov;11(11):1293-303. doi: 10.1586/erv.12.108. Epub 2012 Nov 14. Review.

PMID:
23151111
49.

Burden of paediatric influenza in Western Europe: a systematic review.

Antonova EN, Rycroft CE, Ambrose CS, Heikkinen T, Principi N.

BMC Public Health. 2012 Nov 12;12:968. doi: 10.1186/1471-2458-12-968. Review.

50.

The role of nasal IgA in children vaccinated with live attenuated influenza vaccine.

Ambrose CS, Wu X, Jones T, Mallory RM.

Vaccine. 2012 Nov 6;30(48):6794-801. doi: 10.1016/j.vaccine.2012.09.018. Epub 2012 Sep 18.

Supplemental Content

Loading ...
Support Center